MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutics for endocrine and orphan lung diseases in the United States. The company is headquartered in Westlake Village, California.
| Revenue (TTM) | $393.63M |
| Gross Profit (TTM) | $296.74M |
| EBITDA | $28.14M |
| Operating Margin | -0.76% |
| Return on Equity | 0.00% |
| Return on Assets | 0.79% |
| Revenue/Share (TTM) | $1.42 |
| Book Value | $-0.22 |
| Price-to-Book | 187.85 |
| Price-to-Sales (TTM) | 3.16 |
| EV/Revenue | 3.695 |
| EV/EBITDA | 71.40 |
| Quarterly Earnings Growth (YoY) | -34.90% |
| Quarterly Revenue Growth (YoY) | 42.90% |
| Shares Outstanding | $319.39M |
| Float | $297.53M |
| % Insiders | 1.47% |
| % Institutions | 57.61% |
Volatility is currently expanding
Three revenue streams continue to feed modest growth for MannKind. Two new FDA approvals show promise of turbocharging product growth in two of MNKD's established products. MNKD's existing liquidity should be adequate to fund its operations and launches for ~2.3 years.
MannKind Corporation (MNKD) Q2 2026 Earnings Call Transcript
MannKind NASDAQ: MNKD reported second-quarter revenue of $109.4 million, up 43% from the prior-year period, as growth in its commercial products and collaboration revenue helped offset increased spending tied to product launches and development programs.
MannKind Corporation (MNKD) Discusses Phase 1b Results and Clinical Progress of Nintedanib DPI for IPF Transcript
We also report on an experimental diagnostic approach that can detect tuberculosis exposure and infection at an earlier stage than current methods.
MNKD Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety & Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), today announced that the Company will report second quarter 2026 financial results after market close on Wednesday, August 5, 2026.
MannKind Corporation (MNKD) Discusses FDA Approval of Furoscix ReadyFlow for IV-Equivalent Diuretic Therapy in Fluid Overload Transcript
MannKind NASDAQ: MNKD said the U.S. Food and Drug Administration approved Furoscix ReadyFlow, an auto-injector designed to deliver an 80-milligram dose of subcutaneous furosemide in five to 10 seconds for the management of fluid overload.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on MNKD and any ticker you trade — then tracks every position and per-strategy win rate.
